FDA Updates Quality and Potency Guidance for Cell and Gene Therapies
On November 2, 2026, the U.S. Food and Drug Administration issued final guidance for manufacturers of cellular and gene therapy products. The document sets out recommendations for a Potency Assurance Strategy, replacing previous guidance issued by the agency in 2011. Under federal law, companies making these advanced therapies must verify that every batch meets set standards and works as intended before reaching a patient. These products treat serious or life-threatening conditions, including cancers and rare diseases. Some treatments are customized for a single patient, while others have short shelf lives or rely on viral vectors. For patients relying on these complex medical products, the guidance aims to ensure each dose maintains its strength and biological activity. The FDA plans to host a public webinar on December 10, 2026, to help drug developers understand and adopt the updated framework across every step of production.
What was announced
The U.S. Food and Drug Administration published updated guidance on November 2, 2026, for manufacturers of cellular and gene therapy products. The document outlines recommendations for a Potency Assurance Strategy. This framework guides companies to test and confirm that every product batch meets a set standard of strength before it is given to a patient.
This document replaces the agency's 2011 potency testing guidance. It applies across all stages of development, starting from early investigational new drug applications up to biologics license application approvals and post-market tracking. The guidance addresses specific manufacturing challenges, including raw material variability, short product shelf lives, viral vector gene therapies, and treatments made specifically for individual patients. Karim Mikhail, Director of the FDA's Center for Biologics Evaluation and Research, stated that patients facing serious conditions deserve assurance that their therapies will perform as intended.
What it means
By law, drug manufacturers must prove their products remain effective from approval through commercial distribution. The updated guidance gives drug makers a clearer regulatory path to meet those legal requirements. Potency testing measures whether a medicine has the biological activity needed to produce its intended therapeutic result.
Cellular and gene therapies are among the most complex treatments in medicine. Some are manufactured using a patient's own cells, making standard mass-production quality controls difficult to apply. By establishing risk-based steps for testing throughout production, the FDA aims to prevent batch failures and protect patient safety. The agency will also hold an online session on December 10, 2026, to assist manufacturers with implementing these guidelines.
What the announcement does not tell us
The FDA announcement does not detail specific laboratory test methods or numeric potency thresholds for individual therapies. Because treatments range from viral vectors to personalized cell products, exact testing criteria will depend on each drug's design.
The document also does not state whether existing market products must modify their current testing protocols immediately, nor does it outline specific penalties for non-compliance. Finally, the announcement does not disclose the expected cost for manufacturers to implement these potency assurance strategies.
How this was written
This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is FDA Press Announcements’s own. Always check the original before acting on anything here.
The U.S. Food and Drug Administration today issued final guidance for manufacturers of cellular and gene therapy (CGT) products to implement a comprehensive, science- and risk-based plan for making sure their products meet potency standards.
Opens www.fda.gov
More from FDA Press Announcements
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.